TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease

There is considerable interest in harnessing innate immunity to treat Alzheimer’s disease (AD). Here, we explore whether a decoy receptor strategy using the ectodomain of select TLRs has therapeutic potential in AD. AAV-mediated expression of human TLR5 ectodomain (sTLR5) alone or fused to human IgG...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakrabarty, Paramita, Li, Andrew, Ladd, Thomas B., Strickland, Michael R., Koller, Emily J., Burgess, Jeremy D., Funk, Cory C., Cruz, Pedro E., Allen, Mariet, Yaroshenko, Mariya, Wang, Xue, Younkin, Curtis, Reddy, Joseph, Lohrer, Benjamin, Mehrke, Leonie, Moore, Brenda D., Liu, Xuefei, Ceballos-Diaz, Carolina, Rosario, Awilda M., Medway, Christopher, Janus, Christopher, Li, Hong-Dong, Dickson, Dennis W., Giasson, Benoit I., Price, Nathan D., Younkin, Steven G., Ertekin-Taner, Nilüfer, Golde, Todd E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122970/
https://www.ncbi.nlm.nih.gov/pubmed/30158114
http://dx.doi.org/10.1084/jem.20180484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122970/
https://www.ncbi.nlm.nih.gov/pubmed/30158114
http://dx.doi.org/10.1084/jem.20180484

Ejemplares similares